Evidence map›Paper›PMID 37347290›Full record

SynthesisStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2023

Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review.

Carlotta Becherini, Andrea Lancia, Beatrice Detti, Sara Lucidi, Daniele Scartoni, Gianluca Ingrosso, Maria Grazia Carnevale, Manuele Roghi, Niccolò Bertini, Carolina Orsatti and 9 more

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Carlotta BecheriniRadiation Oncology, Azienda Universitaria Ospedaliera Careggi, Università degli Studi di Firenze, Largo Brambila 1, 50134, Florence, Italy.
Andrea LanciaRadiation Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Beatrice DettiRadiation Oncology, Azienda Universitaria Ospedaliera Careggi, Università degli Studi di Firenze, Largo Brambila 1, 50134, Florence, Italy. Beatrice.detti@aouc.unifi.it.ORCID 0000-0001-9603-2346
Sara LucidiRadiation Oncology, Santa Chiara Hospital, Trento, Italy.
Daniele ScartoniProton Treatment Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
Gianluca IngrossoRadiation Oncology Section, Perugia General Hospital, 06129, Perugia, Italy.
Maria Grazia CarnevaleDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Florence, Italy.
Manuele RoghiDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Florence, Italy.
Niccolò BertiniDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Florence, Italy.
Carolina OrsattiDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Florence, Italy.
Monica MangoniDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Florence, Italy.
Giulio FrancoliniRadiation Oncology, Azienda Universitaria Ospedaliera Careggi, Università degli Studi di Firenze, Largo Brambila 1, 50134, Florence, Italy.
Simona MaraniRadiation Oncology Section, Perugia General Hospital, 06129, Perugia, Italy.
Irene GiacomelliProton Treatment Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
Mauro LoiRadiation Oncology, Azienda Universitaria Ospedaliera Careggi, Università degli Studi di Firenze, Largo Brambila 1, 50134, Florence, Italy.
Stefano PergolizziRadiation Oncology Unit-Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Elisabetta BonzanoRadiation Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Cynthia AristeiRadiation Oncology Section, Perugia General Hospital, 06129, Perugia, Italy.
Lorenzo LiviRadiation Oncology, Azienda Universitaria Ospedaliera Careggi, Università degli Studi di Firenze, Largo Brambila 1, 50134, Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · ITUniversity of Perugia · ITPoliclinico San Matteo Fondazione · ITProvincia Autonoma di Trento · ITOspedale Santa Chiara · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTumor-associated macrophages (TAMs) are the most represented cells of the immune system in the tumor microenvironment (TME). Besides its effects on cancer cells, radiation therapy (RT) can alter TME composition. With this systematic review, we provide a better understanding on how RT can regulate macrophage characterization, namely the M1 antitumor and the M2 protumor polarization, with the aim of describing new effective RT models and exploration of the possibility of integrating radiation with other available therapies.

methodsA systematic search in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was carried out in PubMed, Google Scholar, and Scopus. Articles from January 2000 to April 2020 which focus on the role of M1 and M2 macrophages in the response to RT were identified.

resultsOf the 304 selected articles, 29 qualitative summary papers were included in our analysis (16 focusing on administration of RT and concomitant systemic molecules, and 13 reporting on RT alone). Based on dose intensity, irradiation was classified into low (low-dose irradiation, LDI; corresponding to less than 1 Gy), moderate (moderate-dose irradiation, MDI; between 1 and 10 Gy), and high (high-dose irradiation, HDI; greater than 10 Gy). While HDI seems to be responsible for induced angiogenesis and accelerated tumor growth through early M2-polarized TAM infiltration, MDI stimulates phagocytosis and local LDI may represent a valid treatment option for possible combination with cancer immunotherapeutic agents.

conclusionTAMs seem to have an ambivalent role on the efficacy of cancer treatment. Radiation therapy, which exerts its main antitumor activity via cell killing, can in turn interfere with TAM characterization through different modalities. The plasticity of TAMs makes them an attractive target for anticancer therapies and more research should be conducted to explore this potential therapeutic strategy.

Indexed as

NeoplasmsTumor-Associated MacrophagesHumansMacrophagesTumor MicroenvironmentCancerImmunomodulationMacrophagesRadiobiologyRadiotherapy

Identifiers

PMID37347290
PMCPMC10673745
OpenAlexW4381597773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.